InsidersTradesSigma
Follow the JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €15.9bn. The latest transaction was reported on 27 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ROBERT IANNONE. Every trade is free.
Analysts rate JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Buy (bullish), based on 20 analysts. Average price target: US$286.90.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY is a biopharmaceutical company focused on developing medicines for serious and rare diseases. It is listed on NASDAQ under the ticker symbol JAZZ.